Business
H-CYTE Completes Acquisition of Jantibody
H-CYTE Completes Acquisition of Jantibody.
About this update from Innoveren Scientific Inc.
[{"type":"text","content":"\n TAMPA, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company completed the acquisition of Jantibody. Highlights: Jantibody allows H-CYTE to diversify its asset portfolioFocus indication for ovarian cancer with the potential to be used for other diseases such as mesothelioma and pancreatic cancerH-CYTE plans to submit the Pre-IND submission for Jantibody in the second half of 2022Plan to file for Orphan Drug Designation for Jantibody along with IND submission, which would grant the benefit of 7-year market exclusivityEquity proceeds funded the acquisition of Jantibody “Closing the Jantibody transaction marks a pivotal milestone for the Company as we continue to expand and diversify our portfolio”, said Michael Yurkowsky, H-CYTE’s Chief Executive Officer. “We are excited to take over the rights to this proprietary technology for the treatment of ovarian cancer, the fifth leading cause of cancer-related deaths in women. We expect to submit the Pre-IND submission for Jantibody before the end of 2022. The close of the Jantibody transaction validates H-CYTE’s ongoing transformation into a hybrid-biopharmaceutical company, and we will continue to provide updates as we further expand our portfolio.” Jantibody is a novel cancer immunotherapeutic agent that has demonstrated robust efficacy in controlling ovarian cancer and mesothelioma in preclinical models of these diseases. The Jantibody molecule was developed and refined at the Vaccine and Immunotherapy Center at MGH and Harvard Medical School by Dr. Jeffrey Gelfand and Dr. Mark Poznansky. This molecule is a fusion protein between a broadly immune activating protein called MTBhsp70 and an immune targeting molecule called a single chain antibody which causes the molecule to specifically attach to tumor cells and stimulate a robust immune response specifically around these malignant cells resulting in their death. Jantibody has been shown to work even more effectively in combination with immune checkpoint inhibitors and a CXCR4 antagonist in preclinical models of cancer. The plan at Jantibody is to take this new immunotherapeutic molecule into first in human testing for ovarian cancer, which remains a very difficult to treat disease with current standard of care approache...